Results 31 to 40 of about 26,436 (212)

EFFECT OF LENVATINIB ON THE AUTOPHAGY AND MIGRATION OF CANCER-ASSOCIATED FIBROBLASTS IN HEPATOCELLULAR CARCINOMA TISSUE [PDF]

精准医学杂志, 2023
Objective To investigate the effect of lenvatinib on the autophagy and migration of cancer-associated fibroblasts (CAFs) in hepatocellular carcinoma (HCC) tissue.
ZHAO Ziyin, HE Mingyang, HAN Bing, GUAN Ge, CAI Jinzhen, ZHANG Bin
doaj   +1 more source

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice

Cancer Reports, 2023
Background Lenvatinib monotherapy was approved in the United States for first‐line treatment of patients with unresectable hepatocellular carcinoma (uHCC) in 2018.
Amit G. Singal, Saurabh P. Nagar, Abby Hitchens, Keith L. Davis, Shrividya Iyer   +4 more
doaj   +1 more source

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma

Case Reports in Oncology, 2020
Two tyrosine kinase inhibitors, lenvatinib and sorafenib, are available systemic therapies for patients with metastatic differentiated thyroid carcinoma. However, the treatment options for carcinoma refractory to both lenvatinib and sorafenib are limited.
Masaki Takinami, Tomoya Yokota
doaj   +1 more source

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Frontiers in Oncology, 2021
BackgroundLenvatinib is approved for patients with advanced hepatocellular carcinoma (HCC) due to its non-inferiority to sorafenib of overall survival (OR) in clinical trials.
Yuan-Hung Kuo, Sheng-Nan Lu, Yen-Yang Chen, Kwong-Ming Kee, Yi-Hao Yen, Chao-Hung Hung, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang   +8 more
doaj   +1 more source

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma

Case Reports in Hepatology, 2022
Lenvatinib, an oral small-molecule multiple tyrosine kinase inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC).
Thaninee Prasoppokakorn, Kessarin Thanapirom, Sombat Treeprasertsuk   +2 more
doaj   +1 more source

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series

SAGE Open Medical Case Reports, 2023
Atezolizumab plus bevacizumab is the recommended first-line treatment for unresectable hepatocellular carcinoma, based on guidelines from the Barcelona Clinic Liver Cancer prognosis and treatment strategy.
Takenori Ichimura, Daisuke Ichikura, Miwa Hinata, Noriko Hida, Toshiyuki Baba   +4 more
doaj   +1 more source

Lenvatinib for Anaplastic Thyroid Cancer [PDF]

, 2017
Background: Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Naoko Chayahara, Sasaki, Tatsuya, Chayahara, Naoko, Kenji Nakano, Makoto Tahara, Hironobu Minami, Shunji Takahashi, Suzuki, Takuya, Corina E. Dutcus, Enokida, Tomohiro, Toda, Kazuhisa, Yoshinori Imamura, Dutcus, Corina E., Imamura, Yoshinori, Inagaki, Lina, Takahashi, Shunji, Kiyota, Naomi, Fujino, Katsuki, Naomi Kiyota, Tomoko Yamazaki, Lina Inagaki, Takuya Suzuki, Katsuki Fujino, Tatsuya Sasaki, Tomohiro Enokida, Yamazaki, Tomoko, Tahara, Makoto, Minami, Hironobu, Nakano, Kenji, Kazuhisa Toda   +29 more
core   +1 more source

Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma

Cells, 2023
Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits ...
Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuma Wada, Hiroki Teraoku, Shinichiro Yamada, Yu Saito, Tetsuya Ikemoto, Mitsuo Shimada, Ajay Goel   +10 more
doaj   +1 more source

Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma

Discover Oncology, 2023
Background Hepatocellular carcinoma (HCC) is one of the most common malignant cancers in humans and has a high fatality rate. Despite pharmacological advances such as sorafenib and lenvatinib approval, responses are seen only in a limited fraction of ...
Danyan Gu, Meng Tong, Jing Wang, Bocheng Zhang, Jinghua Liu, Guoqiang Song, Biao Zhu   +6 more
doaj   +1 more source

Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma

, 2023
Cheng Zhou,1,* Zhang-Fu Yang,1,* Bao-Ye Sun,1,* Yong Yi,1 Zheng Wang,1 Jian Zhou,1 Jia Fan,1 Wei Gan,1 Ning Ren,1,2 Shuang-Jian Qiu1 1Department of Liver Surgery and Transplantation & Key Laboratory of Carcinogenesis and Cancer Invasion ...
Yi Y, Yang ZF, Fan J, Zhou C, Ren N, Wang Z, Gan W, Sun BY, Zhou J, Qiu SJ   +9 more
core